524 related articles for article (PubMed ID: 17139594)
1. [Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors].
Ghofrani HA; Grimminger F
Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S311-4. PubMed ID: 17139594
[TBL] [Abstract][Full Text] [Related]
2. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
4. Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction.
Shabsigh R; Seftel AD; Rosen RC; Porst H; Ahuja S; Deeley MC; Garcia CS; Giuliano F
Urology; 2006 Oct; 68(4):689-96. PubMed ID: 17070333
[No Abstract] [Full Text] [Related]
5. [Erectile dysfunction (ED) and diabetes mellitus].
Takahashi Y
Nihon Rinsho; 2005 Jun; 63 Suppl 6():553-7. PubMed ID: 15999768
[No Abstract] [Full Text] [Related]
6. PDE-5 inhibitors: current status and future trends.
Masson P; Lambert SM; Brown M; Shabsigh R
Urol Clin North Am; 2005 Nov; 32(4):511-25, viii. PubMed ID: 16291042
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.
Michelakis ED; Tymchak W; Noga M; Webster L; Wu XC; Lien D; Wang SH; Modry D; Archer SL
Circulation; 2003 Oct; 108(17):2066-9. PubMed ID: 14568893
[TBL] [Abstract][Full Text] [Related]
8. Sildenafil in neonatal pulmonary hypertension due to impaired alveolarisation and plexiform pulmonary arteriopathy.
Chaudhari M; Vogel M; Wright C; Smith J; Haworth SG
Arch Dis Child Fetal Neonatal Ed; 2005 Nov; 90(6):F527-8. PubMed ID: 16244212
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension.
Bharani A; Mathew V; Sahu A; Lunia B
Indian Heart J; 2003; 55(1):55-9. PubMed ID: 12760589
[TBL] [Abstract][Full Text] [Related]
10. [Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension].
Sakuma M; Shirato K
Nihon Rinsho; 2008 Nov; 66(11):2157-61. PubMed ID: 19051736
[TBL] [Abstract][Full Text] [Related]
11. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F
J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333
[TBL] [Abstract][Full Text] [Related]
12. Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension.
Schwartz BG; Kloner RA
Circulation; 2010 Jul; 122(1):88-95. PubMed ID: 20606131
[No Abstract] [Full Text] [Related]
13. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
Tsai BM; Turrentine MW; Sheridan BC; Wang M; Fiore AC; Brown JW; Meldrum DR
Ann Thorac Surg; 2006 Jan; 81(1):272-8. PubMed ID: 16368379
[TBL] [Abstract][Full Text] [Related]
14. Sildenafil citrate therapy for pulmonary arterial hypertension.
Izbicki G; Rosengarten D; Picard E
N Engl J Med; 2006 Mar; 354(10):1091-3; author reply 1091-3. PubMed ID: 16528809
[No Abstract] [Full Text] [Related]
15. Sildenafil in pulmonary hypertension.
Nanivadekar A
Indian Heart J; 2003; 55(3):285; author reply 285. PubMed ID: 14560947
[No Abstract] [Full Text] [Related]
16. Sildenafil citrate therapy for pulmonary arterial hypertension.
Kuschner WG
N Engl J Med; 2006 Mar; 354(10):1091-3; author reply 1091-3. PubMed ID: 16528810
[No Abstract] [Full Text] [Related]
17. [Phosphodiesterase inhibitors in clinical practice. The present and the future. Part II].
Baksheev BI; Kolomiets NM
Klin Med (Mosk); 2007; 85(4):4-11. PubMed ID: 17564028
[TBL] [Abstract][Full Text] [Related]
18. Sildenafil in primary pulmonary hypertension.
Prasad S; Wilkinson J; Gatzoulis MA
N Engl J Med; 2000 Nov; 343(18):1342. PubMed ID: 11183578
[No Abstract] [Full Text] [Related]
19. Phosphodiesterase inhibitors for pulmonary hypertension.
Galiè N; Rubin LJ; Simonneau G
N Engl J Med; 2010 Feb; 362(6):559-60; author reply 560. PubMed ID: 20175298
[No Abstract] [Full Text] [Related]
20. Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension.
Hemnes AR; Champion HC
Expert Rev Cardiovasc Ther; 2006 May; 4(3):293-300. PubMed ID: 16716091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
